HealthQuest Capital supplied $75m for the medical test provider, which counts The Chernin Group as an investor, at a flat $1.3bn valuation.

Everlywell, the US-based medical test provider backed by over-the-top media company The Chernin Group, has received $75m in funding from venture capital firm HealthQuest Capital, TechCrunch has reported.

Founded in 2015, Everlywell offers a range of at-home testing kits for conditions such as covid-19, lyme disease and sexually transmitted infections in addition to those testing food allergies and sensitivities or cholesterol, vitamin D or testosterone levels.

The capital was supplied at the same $1.3bn valuation at which Everlywell last raised…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.